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ABSTRACT: Overexpression of anti-apoptotic proteins such as Bcl-2 is a
cellular mechanism to evade apoptosis; consequently, Bcl-2 inhibitors are being
developed as anticancer agents. In this work, we have synthesized a ﬂuorescent
version of ABT-199 in an eﬀort to visualize a drug surrogate by high resolution
imaging. We show that this ﬂuorescent conjugate has comparable Bcl-2 binding
eﬃcacy and cell line potency to the parent compound and can be used as an
imaging agent in several cancer cell types. We anticipate that this agent will be a
valuable tool for studying the single-cell distribution and pharmacokinetics of
ABT-199 as well the broader group of BH3-mimetics.
■ INTRODUCTION
Proteins that regulate cellular apoptotic machinery are critical
mediators of cell fate. Overexpression of anti-apoptotic
proteins, particularly the B-cell lymphoma 2 (Bcl-2) family of
proteins, is one mechanism by which cancer cells evade cell
death and become resistant to chemotherapeutic agents. A set
of new drug candidates, known as BH3 mimetics, have been
developed to target these proteins; several of these candidates
are currently undergoing clinical trials. To date, clinical trials
have focused mostly on hematopoietic cancers whereas
application of these drugs in solid tumors both as single agents
and as cotherapeutics is an emerging strategy. Unfortunately, it
has not been possible to visualize the distribution of such
inhibitors in tumor cells in vivo, making it challenging to
determine how eﬀects might vary as a function of tumor type,
location, dosing, and other variables. In short, it would be
desirable to have a ﬂuorescent companion imaging drug (CID)
to explore the spatiotemporal kinetics in vivo.
Bcl-2 plays a fundamental role in cell biology via interactions
with a number of other critical proteins, including the pro-
apoptotic Bcl-2 family members Bcl-2-associated death
promoter (BAD), Bcl-2-antagonist/killer 1 (BAK), Bcl-2
interacting mediator of cell death (BIM), and Bcl-2 associated
protein X (BAX).1−4 Other closely related family members with
an anti-apoptotic role exist (Bcl-xL, Bcl2A1, Bcl-w, and Mcl-1),
which interact with pro-apoptotic proteins.4,5 In normal cells,
following receipt of a death signal, pro-apoptotic proteins
function to permeabilize the outer mitochondrial membrane in
order to initiate release of cytochrome c, which combines with
apoptosis activating factor (APAF-1) to form apoptosomes,
ultimately resulting in apoptosis.6,7 Anti-apoptotic proteins
inhibit this initiation by a range of interactions with pro-
apoptotic proteins. For example, Bcl-2 plays a critical role in
this process by preventing cytochrome c release via interactions
with BAK/BAX, inhibiting pore formation in the outer
mitochondrial membrane.8,9 The balance of pro- and anti-
apoptotic proteins therefore determines overall cell suscepti-
bility to normal apoptotic signaling.10
Several pan-Bcl-2 family protein inhibitors, including
obatoclax (GX15−070),11 gossypol/levo-gossypol (AT-101),12
ABT-737,13 and its orally bioavailable successor Navitoclax
(ABT-263) (Figure 1A)14,15 have been developed; all of these
inhibitors have strong interactions with a range of anti-
apoptotic proteins. For example, ABT-263 has high aﬃnity for
almost all Bcl-2 family anti-apoptotic proteins (Ki <550 nM for
Bcl-2, Bcl-xL, Mcl-1, Bcl-w, and Bcl2A1).5 Despite the initial
promise of ABT-263, dose-limiting toxicities were observed
from induction of thrombocytopenia, likely due to inhibition of
Bcl-xL in platelets.16 Through rational modiﬁcation of the ABT-
263 scaﬀold, ABT-199 was developed to selectively target Bcl-2
(Figure 1B).16,17 This selectivity makes ABT-199 an attractive
candidate for development of a CID. The ABT-199 scaﬀold
lends itself to analog generation via a convergent synthetic
approach that involves the exchange of a moiety in ABT-199
that is not critical for Bcl-2 aﬃnity. Speciﬁcally, the
tetrahydropyranyl substituent was exchanged for a piperidine
bearing an aminoethyl-linker for conjugation to ﬂuorophores
(e.g., BODIPY-FL). We demonstrate that the described CID
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maintains aﬃnity for Bcl-2 both in vitro and in cellular assays.
Furthermore, we show that this agent has high localization to
mitochondria (a primary location of Bcl-2 proteins) in cancer
cell lines and has shown excellent uptake across a range of
tumor lines. Because there is increasing interest in translating
ABT-199 into solid tumor therapies in both mono and dual
treatment modalities, this CID may be a useful tool for
understanding inter- and intracellular localization and hetero-
geneity of the distribution of Bcl-2 inhibitors.
■ RESULTS
We used both the published crystal structure of Bcl-2 bound to
an ABT-199/ABT-263 analog (PDB 4MAN) (Figure 1C) and
relevant details related to the BH3-mimetic design to determine
available modiﬁcation sites of ABT-199. From both NMR
structural analysis15 and crystal structure data, it has been
established that pro-apoptotic proteins (i.e., BH3 proteins)
bind to a groove (approximately 20 Å long), that is composed
of two main hydrophobic bonding pockets termed P2 and P4
(Figure 1C).15,18−20 As described by Souers et al.,16 the
structure of ABT-199 was developed by reverse-engineering of
ABT-263 based on slight structural diﬀerences in the P4
binding pockets of Bcl-2 and Bcl-xL, namely, the presence of
Asp103 in Bcl-2 versus Glu96 in Bcl-xL. Notably, removal of
the thiophenolic ether of ABT-263 and incorporation of a 7-
azaindole moiety imparted the desired selectivity. The
importance of the P2 and P4 binding sites as well as the
azaindole moiety in ABT-199 prompted us to modify a portion
of the molecule that only occupies the edge of the P4 binding
site. We substituted the tetrahydropyranyl moiety of ABT-199
with a piperidine; the piperidine was elaborated with an
aminoethyl- linker for facile attachment of ﬂuorophores.
The de novo synthesis (Figure 2) of ABT-199-BODIPY
(Figure 1D) was accomplished in 17 steps (11 in the longest
linear sequence). The complete synthetic schemes and
procedures are provided in the Supporting Information.
Starting from known acid 1, ABT-199 analog 3 was generated
after coupling with aryl sulfonamide 2. Sulfonamide 2 was
synthesized via nucleophilic aromatic substitution of commer-
cially available 4-ﬂuoro-3-nitrobenzenesulfonamide with tert-
butyl 4-(aminomethyl)piperidine-1-carboxylate 6. Removal of
the Boc protecting group with HCl in dioxane followed by
alkylation with 1-N-(2-bromoethyl)carbamate aﬀorded 2.
Following the EDCI-mediated coupling of 1 and 2 to generate
3, the Boc protecting group was removed using triﬂuoroacetic
acid (TFA) and Et3SiH (as a scavenger) followed by reaction
Figure 1. Design of ABT-199-BODIPY. (A,B) Chemical structures of
BH3-mimetics ABT-263 (Navitoclax) and ABT-199, (C) Crystal
structure of an ABT-199 analog bound to Bcl-2 (PDB 4MAN),
generated using The PyMOL Molecular Graphics System, v 1.5.0.4
Schrödinger, LLC. (D) Structure of the ﬂuorescent companion
imaging drug (CID) based on the structure of ABT-199.
Figure 2. Synthesis of ABT-199-BODIPY.
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with the N-hydroxysuccinimidyl ester of BODIPY FL to aﬀord
ABT-199-BODIPY 8. The synthesis of ABT-199-BODIPY is
convergent; it would be possible to test other modiﬁcations by
generating libraries of aryl sulfonamides (accessible in 2−3
steps from commercially available materials) and coupling to
intermediate acid 1. ABT-199-BODIPY was obtained in ca. 9%
overall yield over the longest linear sequence. The purity was
>95% based on LC-MS analysis (using both evaporative light
scattering detection (ELSD) and UV/vis detection for
determining purity).
To validate that ABT-199-BODIPY maintains eﬃcacy against
Bcl-2, we ﬁrst performed a competitive binding experiment
(Figure 3A). This experiment was carried out by incubating
puriﬁed Bcl-2 protein with either ABT-199-BODIPY, the
piperidine-substituted analog 3, or ABT-199 (Figure 3A). The
binding was assessed using an ELISA-type format wherein the
protein/inhibitor complexes were applied to a surface of
immobilized BIM peptide.21 We found that substituting the
ABT-199 tetrahydropyran for the N-aminoethylpiperidine
(compound 3) resulted in a 2-fold loss in activity; further
elaboration with the BODIPY subsituent resulted in a 4-fold
loss of activity; still, the modiﬁed ABT-199 scaﬀolds show
excellent inhibitory activity for disruption of the Bcl-2/BIM
protein−protein interaction.
We next determined the eﬀects of ABT-199-BODIPY on the
viability of RL cells (a human non-Hodgkin’s lymphoma
derived cell line) which have been shown to have high levels of
Bcl-2 and are therefore selectively sensitive to treatment with
BH3 mimetics (Figure 3B).16 ABT-199-BODIPY is ∼12 times
less eﬀective toward inducing cell death in the RL cell lines, but
it is still equipotent with ABT-263, an agent currently in phase
II clinical trials. The slight decrease in activity may stem from
decreased solubility of ABT-199-BODIPY or reduced aﬃnity of
ABT-199-BODIPY due to the addition of the bulkier
ﬂuorophore substituent. ABT-199, ABT-263, and ABT-199-
BODIPY were ineﬀective at inducing cell death in cell lines that
do not overexpress Bcl-2, including OVCA-429 and MDA-MB-
231 (EC50 > 10 μM, Supporting Information Figure S5).
We next examined the intracellular distribution of ABT-199-
BODIPY and its colocalization with apoptosis speciﬁc cell
components. We ﬁrst incubated OVCA-429 cells with ABT-
199-BODIPY (1 μM, overnight incubation, a concentration
shown to be nontoxic to cell lines without speciﬁc Bcl-2
dependency; see Supporting Information Figure S5). We
observed localization of the imaging drug to mitochondria
(Figure 4) as determined by immunocytochemistry. We next
imaged the intracellular distribution of ABT-199-BODIPY in
live cells. MDA-MB-231 cells transfected with a Bcl-2-RFP
reporter were treated with ABT-199-BODIPY (5 μM 1 h
before imaging (Figure 5)). In this cell line, Bcl-2 was observed
in the mitochondria in addition to the endoplasmic reticulum
and as a cytosolic protein. Addition of ABT-199-BODIPY
showed excellent colocalization of the compound with areas of
Bcl-2-RFP fusion protein. We similarly assessed whether ABT-
199-BODIPY would show similar uptake and localization across
a panel of cancer cell lines. Common cell lines (OVCA-429,
Panc-1, MDA-MB-231, MCF-7, 4T1, A431, and HT-1080)
Figure 3. Eﬃcacy of ABT-199-BODIPY. (A) Data from an ELISA-
based in vitro competitive binding experiment. Varying concentrations
of inhibitors were incubated with puriﬁed His-tagged Bcl-2 protein (20
nM) for 2 h, then applied to a BIM-coated surface (biotinylated BIM
peptide was covalently bound to a Streptavidin-coated plate). The
amount of protein bound was quantiﬁed after incubation with anti-
His_HRP antibody and spectrophotochemical measurement using
ortho-phenylenediamine as a substrate. (B) Viability of RL cells after
incubating with BH3-mimetics for 48 h.
Figure 4. Immunocytochemistry illustrating mitochondrial colocaliza-
tion of ABT-199-BODIPY in a single OVCA-429 cell. (A) DAPI, (B)
ABT-199-BODIPY, (C) TOMM-20 antibody (Mitochondria), (D)
Merged imaged (DAPI, blue; ABT-199, green; Mitochondria, red).
Scale bar is 5 μm.
Figure 5. Live cell imaging of ABT-199-BODIPY and Bcl-2 in MDA-
MB-231 cells. (A) ABT-199-BODIPY, (B) Bcl-2-RFP, (C) Colocaliza-
tion of ABT-199-BODIPY (green) and Bcl-2 (red), (D) Colocaliza-
tion scatter plot of ABT-199-BODIPY and Bcl-2. The Pearson
coeﬃcient was 0.9899 and Manders I &II were >0.99. Scale bar is 10
μm.
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were incubated with ABT-199-BODIPY (1 μM) overnight,
ﬁxed, counterstained with DAPI, and observed (Figure 6).
Across all cell lines we noted excellent uptake of the CID and
colocalization with mitochondria-like structures (Supporting
Information Figure S6) in addition to more limited cytosolic
and other organelle staining consistent with known local-
izations of Bcl-2 (Figure 5).
■ DISCUSSION
The regulation of intrinsic apoptosis events by Bcl-2 family
proteins plays a key role in cell fate. Overexpression of Bcl-2
proteins is a common cancer cell survival mechanism.
Furthermore, increased expression of Bcl-2 family proteins is
a cause of acquired resistance to chemotherapeutic agents.
Recently, cancer therapies that target Bcl-2 proteins have
shown promise in clinical trials,22 but little is known regarding
the single cell pharmacokinetics, intracellular dynamics, and
heterogeneity of distribution of these inhibitors as well as their
protein-speciﬁc responses.
Current approaches for probing the cellular response of Bcl-2
protein mediated interactions include BH3 proﬁling, which
measures mitochondrial response to BH3-only peptides and is
thus predictive of Bcl-2 targeted probes such as ABT-199.23,24
To understand protein speciﬁc dynamics, ﬂuorescence lifetime
imaging microscopy (FLIM) using ﬂuorescent proteins (e.g.,
Venus-Bcl-xL and mCherry-BAD) has also been used to study
real-time protein/protein interactions after treatment with
inhibitors, but this method does not address the intra- and
intercellular distribution of inhibitor.25,26 To date it has not
been possible to directly visualize Bcl-2 inhibitor distribution in
live cells.
The increasing interest in targeting Bcl-2 family proteins in
nonhematological cancers and solid tumors underscores the
need for agents that monitor the distribution and heterogeneity
of drug distribution. In this work, we designed and synthesized
a structurally matched companion imaging drug (CID) for
ABT-199 that can be used as a tool for studying the subcellular
localization and pharmacokinetics of Bcl-2 inhibitors. We
anticipate that the CID will enable inhibitor localization studies
as well as spatiotemporal studies in live cells and tumors.
Although we have demonstrated that this CID can be utilized in
a range of cancer cells, further testing will be required to move
this CID into animal models. The use of such a tool compound
could provide compelling insight toward developing appro-
priate dual therapy treatment regimens and understanding how
cell physiology aﬀects the uptake, localization, and cellular
response of BH3-mimetics.
■ ASSOCIATED CONTENT
*S Supporting Information
Procedures for chemical synthesis and associated spectra, cell
culture and in vitro assays, cell imaging as well as descriptions
of all materials and instrumentation. This material is available
free of charge via the Internet at http://pubs.acs.org.
■ AUTHOR INFORMATION
Corresponding Author
*Phone: 617-726-8226. E-mail: rweissleder@mgh.harvard.edu.
Author Contributions
Randy J. Giedt and Melissa M. Sprachman contributed equally
to this work.
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
R.J.G. and M.M.S. were supported by an NIH grant
T32CA79443, and th is pro ject was funded via
1R01CA164448 and P01-CA139980. We are grateful to Dr.
Rainer Kohler for imaging assistance and Dr. Thomas Reiner,
Dr. Bjorn Askevold, and Dr. Eunha Kim for many helpful
discussions. The crystal structure graphic of Bcl-2 used in the
TOC graphic was generated using CCP4 mg Molecular
Graphics Software.27
■ ABBREVIATIONS
EDCI, 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide;
DMAP, 4-dimethylaminopyridine; TFA, triﬂuoroacetic acid;
THF, tetrahydrofuran; DMF, N,N-dimethylformamide; BOD-
IPY FL, SE, 7-(2-carboxyethyl)-5,5-diﬂuoro-1,3-dimethyl-5H-
dipyrrolo[1,2-c:2′,1′-f ][1,3,2]diazaborinin-4-ium-5-uide, N-hy-
droxysuccinimidyl ester; Boc, tert-butyloxycarbonyl
■ REFERENCES
(1) Murphy, K. M., Ranganathan, V., Farnsworth, M. L., Kavallaris,
M., and Lock, R. B. (2000) Bcl-2 inhibits Bax translocation from
cytosol to mitochondria during drug-induced apoptosis of human
tumor cells. Cell Death Differ. 7, 102−111.
(2) Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. (1993) Bcl-2
heterodimerizes in vivo with a conserved homolog, Bax, that
accelerates programmed cell death. Cell 74, 609−619.
(3) Sedlak, T. W., Oltvai, Z. N., Yang, E., Wang, K., Boise, L. H.,
Thompson, C. B., and Korsmeyer, S. J. (1995) Multiple Bcl-2 family
members demonstrate selective dimerizations with Bax. Proc. Natl.
Acad. Sci. U. S. A. 92, 7834−7838.
(4) Rual, J. F., Venkatesan, K., Hao, T., Hirozane-Kishikawa, T.,
Dricot, A., Li, N., Berriz, G. F., Gibbons, F. D., Dreze, M., Ayivi-
Guedehoussou, N., Klitgord, N., Simon, C., Boxem, M., Milstein, S.,
Rosenberg, J., Goldberg, D. S., Zhang, L. V., Wong, S. L., Franklin, G.,
Li, S., Albala, J. S., Lim, J., Fraughton, C., Llamosas, E., Cevik, S., Bex,
C., Lamesch, P., Sikorski, R. S., Vandenhaute, J., Zoghbi, H. Y.,
Smolyar, A., Bosak, S., Sequerra, R., Doucette-Stamm, L., Cusick, M.
E., Hill, D. E., Roth, F. P., and Vidal, M. (2005) Towards a proteome-
scale map of the human protein-protein interaction network. Nature
437, 1173−1178.
(5) Vogler, M., Dinsdale, D., Dyer, M. J., and Cohen, G. M. (2009)
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.
Cell Death Differ. 16, 360−367.
Figure 6. ABT-199-BODIPY localization across a panel of cancer cell
lines (DAPI, blue; ABT-199-BODIPY; green). (A) OVCA-429, (B)
MCF-7, (C) 4T1, (D) A431, (E) HT-1080, (F) Panc-1, (G) MDA-
MB-231. Scale Bar is 50 μm.
Bioconjugate Chemistry Article
dx.doi.org/10.1021/bc500433k | Bioconjugate Chem. 2014, 25, 2081−20852084
(6) Zou, H., Henzel, W. J., Liu, X., Lutschg, A., and Wang, X. (1997)
Apaf-1, a human protein homologous to C. elegans CED-4,
participates in cytochrome c-dependent activation of caspase-3. Cell
90, 405−413.
(7) Milam, S. L., Nicely, N. I., Feeney, B., Mattos, C., and Clark, A. C.
(2007) Rapid folding and unfolding of Apaf-1 CARD. J. Mol. Biol. 369,
290−304.
(8) Yang, J., Liu, X., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J.,
Peng, T. I., Jones, D. P., and Wang, X. (1997) Prevention of apoptosis
by Bcl-2: release of cytochrome c from mitochondria blocked. Science
275, 1129−1132.
(9) Komatsu, K., Miyashita, T., Hang, H., Hopkins, K. M., Zheng, W.,
Cuddeback, S., Yamada, M., Lieberman, H. B., and Wang, H. G.
(2000) Human homologue of S. pombe Rad9 interacts with Bcl-2/Bcl-
xL and promotes apoptosis. Nat. Cell Biol. 2, 1−6.
(10) Youle, R. J., and Strasser, A. (2008) The BCL-2 protein family:
opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9,
47−59.
(11) Reed, J. C., and Pellecchia, M. (2005) Apoptosis-based therapies
for hematologic malignancies. Blood 106, 408−418.
(12) Paulus, A., Chitta, K., Akhtar, S., Personett, D., Miller, K. C.,
Thompson, K. J., Carr, J., Kumar, S., Roy, V., Ansell, S. M., Mikhael, J.
R., Dispenzieri, A., Reeder, C. B., Rivera, C. E., Foran, J., and Chanan-
Khan, A. (2014) AT-101 downregulates BCL2 and MCL1 and
potentiates the cytotoxic effects of lenalidomide and dexamethasone in
preclinical models of multiple myeloma and Waldenstrom macro-
globulinaemia. Br. J. Hamaetol. 164, 352−365.
(13) Trudel, S., Stewart, A. K., Li, Z., Shu, Y., Liang, S. B., Trieu, Y.,
Reece, D., Paterson, J., Wang, D., and Wen, X. Y. (2007) The Bcl-2
family protein inhibitor, ABT-737, has substantial antimyeloma activity
and shows synergistic effect with dexamethasone and melphalan. Clin.
Cancer Res. 13, 621−629.
(14) Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R.
C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J.,
Hajduk, P. J., Joseph, M. K., Kitada, S., Korsmeyer, S. J., Kunzer, A. R.,
Letai, A., Li, C., Mitten, M. J., Nettesheim, D. G., Ng, S., Nimmer, P.
M., O’Connor, J. M., Oleksijew, A., Petros, A. M., Reed, J. C., Shen,
W., Tahir, S. K., Thompson, C. B., Tomaselli, K. J., Wang, B., Wendt,
M. D., Zhang, H., Fesik, S. W., and Rosenberg, S. H. (2005) An
inhibitor of Bcl-2 family proteins induces regression of solid tumours.
Nature 435, 677−681.
(15) Wendt, M. D. (2012) The discovery of Navitoclax, a Bcl-2
family inhibitor. Top. Med. Chem. 8, 231−258.
(16) Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L.,
Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H.,
Fairbrother, W. J., Huang, D. C., Hymowitz, S. G., Jin, S., Khaw, S. L.,
Kovar, P. J., Lam, L. T., Lee, J., Maecker, H. L., Marsh, K. C., Mason,
K. D., Mitten, M. J., Nimmer, P. M., Oleksijew, A., Park, C. H., Park, C.
M., Phillips, D. C., Roberts, A. W., Sampath, D., Seymour, J. F., Smith,
M. L., Sullivan, G. M., Tahir, S. K., Tse, C., Wendt, M. D., Xiao, Y.,
Xue, J. C., Zhang, H., Humerickhouse, R. A., Rosenberg, S. H., and
Elmore, S. W. (2013) ABT-199, a potent and selective BcL-2 inhibitor,
achieves antitumor activity while sparing platelets. Nat. Med. 19, 202−
208.
(17) Davids, M. S., and Letai, A. (2013) ABT-199: taking dead aim at
Bcl-2. Cancer Cell 23, 139−141.
(18) Wendt, M. D., Shen, W., Kunzer, A., McClellan, W. J., Bruncko,
M., Oost, T. K., Ding, H., Joseph, M. K., Zhang, H., Nimmer, P. M.,
Ng, S. C., Shoemaker, A. R., Petros, A. M., Oleksijew, A., Marsh, K.,
Bauch, J., Oltersdorf, T., Belli, B. A., Martineau, D., Fesik, S. W.,
Rosenberg, S. H., and Elmore, S. W. (2006) Discovery and structure-
activity relationship of antagonists of B-cell lymphoma 2 family
proteins with chemopotentiation activity in vitro and in vivo. J. Med.
Chem. 49, 1165−1181.
(19) Bruncko, M., Oost, T. K., Belli, B. A., Ding, H., Joseph, M. K.,
Kunzer, A., Martineau, D., McClellan, W. J., Mitten, M., Ng, S. C.,
Nimmer, P. M., Oltersdorf, T., Park, C. M., Petros, A. M., Shoemaker,
A. R., Song, X., Wang, X., Wendt, M. D., Zhang, H., Fesik, S. W.,
Rosenberg, S. H., and Elmore, S. W. (2007) Studies leading to potent,
dual inhibitors of Bcl-2 and Bcl-xL. J. Med. Chem. 50, 641−662.
(20) Ni Chonghaile, T., and Letai, A. (2008) Mimicking the BH3
domain to kill cancer cells. Oncogene 27 (Suppl 1), S149−S157.
(21) Wang, G., Nikolovska-Coleska, Z., Yang, C. Y., Wang, R., Tang,
G., Guo, J., Shangary, S., Qiu, S., Gao, W., Yang, D., Meagher, J.,
Stuckey, J., Krajewski, K., Jiang, S., Roller, P. P., Abaan, H. O., Tomita,
Y., and Wang, S. (2006) Structure-based design of potent small-
molecule inhibitors of anti-apoptotic Bcl-2 proteins. J. Med. Chem. 49,
6139−6142.
(22) Scarfo, L., and Ghia, P. (2013) Reprogramming cell death:
BCL2 family inhibition in hematological malignancies. Immunol. Lett.
155, 36−39.
(23) Certo, M., Del Gaizo Moore, V., Nishino, M., Wei, G.,
Korsmeyer, S., Armstrong, S. A., and Letai, A. (2006) Mitochondria
primed by death signals determine cellular addiction to antiapoptotic
BCL-2 family members. Cancer Cell 9, 351−365.
(24) Vo, T. T., Ryan, J., Carrasco, R., Neuberg, D., Rossi, D. J., Stone,
R. M., Deangelo, D. J., Frattini, M. G., and Letai, A. (2012) Relative
mitochondrial priming of myeloblasts and normal HSCs determines
chemotherapeutic success in AML. Cell 151, 344−355.
(25) Kale, J., Liu, Q., Leber, B., and Andrews, D. W. (2012) Shedding
light on apoptosis at subcellular membranes. Cell 151, 1179−1184.
(26) Aranovich, A., Liu, Q., Collins, T., Geng, F., Leber, B., and
Andrews, D. W. (2012) Differences in the mechanisms of
proapoptotic BH3 proteins binding to Bcl-XL an d Bcl-2 quantified
in live MCF-7 cells. Mol. Cell 45, 754−763.
(27) McNicholas, S., Potterton, E., Wilson, K. S., and Noble, M. E.
M. (2011) Presenting your structures: the CCP4mg molecular-
graphics software. Acta Crystallogr., Sect. D 67, 386−94.
Bioconjugate Chemistry Article
dx.doi.org/10.1021/bc500433k | Bioconjugate Chem. 2014, 25, 2081−20852085
